^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
CLL/SLL with del(17p)/TP53 mutation: First-line therapy...Preferred regimens… HDMP + Rituximab
Secondary therapy:
methylprednisolone oral